Best Health & Fitness Stocks to Buy as Wellness Demand Grows

Zacks highlights Vita Coco, Garmin and Herbalife as health-and-fitness beneficiaries of a global wellness market projected to reach $7.76 trillion by 2035, representing a 4.94% CAGR from 2026. Garmin cited healthy demand for premium wearables and expects fitness to be its largest growth contributor in 2026, supported by new Forerunner watches and the CIRQA Smart Band. Vita Coco is expanding functional hydration offerings, while Herbalife is broadening nutrition, weight-management and coaching products across 95 markets.

Analysis

This is low-information promotional research, not a fundamental catalyst; the broad wellness theme is already embedded in consensus growth narratives. The actionable distinction is business-model quality: GRMN can turn device adoption into higher lifetime value through software, coaching and service attach, whereas COCO remains principally a branded beverage execution story with retailer shelf-space, promotional spending and agricultural-input sensitivity. AAPL's installed-base advantage keeps it the central ecosystem risk for standalone wearable vendors, but GRMN's endurance/outdoor specialization is less substitutable than mass-market smartwatch demand.

Over the next 1-3 months, GRMN is the cleanest watch item: premium wearable unit growth, fitness-segment mix and any evidence that acquired coaching assets raise recurring revenue rather than merely add integration cost. A sustained subscription/engagement uplift could justify a multiple premium versus hardware peers over 6-18 months; weak attach rates would instead expose the stock to mature-hardware valuation. The key falsifier is a fitness revenue deceleration accompanied by gross-margin pressure from product mix or price competition.

COCO's strategic risk is that functional hydration is crowded by much better-capitalized beverage distributors and brands, making category growth more likely to manifest as promotional intensity than durable price realization. For HLF, wellness-product launches do not address the core underwriting issues: distributor productivity, regulatory/reputation overhang and leverage. GLP-1 adoption is a two-sided variable—weight-management demand can expand awareness, but treatment-driven weight loss may reduce demand for traditional meal-replacement regimens unless HLF demonstrates retention or credible complementary positioning.

Contrarian view: the investable expression of preventive health may be neither supplements nor commodity-like devices, but data ownership and clinical workflow integration. That favors AAPL and AMZN strategically, though the cited initiatives are far too immaterial to alter either company's near-term estimates. Do not extrapolate thematic market-size forecasts into revenue forecasts for the smaller names without measured distribution gains, repeat purchase rates and contribution-margin evidence.

Key Decisions for Investors

• Maintain a 3-6 month watch-long bias in GRMN; initiate only after the next earnings release confirms fitness revenue growth above company growth and stable/improving segment margin. Target 10-15% upside on a recurring-revenue re-rating; exit on fitness guidance reduction or a material gross-margin miss.
• Avoid chasing COCO on thematic headlines. Reassess after 1-2 quarterly reports only if measured retail distribution, repeat velocity and gross margin improve simultaneously; otherwise category expansion is likely to accrue to scaled beverage competitors such as KO and PEP through distribution economics.
• Use HLF as a tactical short/watch-short against a long GRMN position over 3-6 months only if distributor metrics weaken or net debt/EBITDA fails to decline. The pair isolates higher-quality connected-fitness monetization from direct-selling and GLP-1 substitution risk; cover on demonstrable volume-point acceleration and deleveraging.
• No incremental AAPL or AMZN position is warranted from this item. Set an alert for disclosed healthcare-service monetization, reimbursed clinical partnerships or material wearable health-feature adoption; without those data, wellness remains strategically relevant but financially immaterial.